Advertisement

Document › Details
ERS Genomics Ltd.. (3/3/21). "Press Release: ERS Genomics Licenses CRISPR Gene Editing Technology to Otsuka Pharmaceutical". Dublin.
License to Nobel prize winning CRISPR technology supports internal research and development
ERS Genomics Limited, which was formed to provide broad access to foundational CRISPR/Cas9 intellectual property today announced the signing of a license agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka). The license grants Otsuka access to CRISPR/Cas9 genome editing technology for its internal research and development initiatives to address areas of unmet medical need.
ERS Genomics holds an exclusive worldwide license from co-founder and recent Nobel prize winner Dr. Emmannuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform.
Eric Rhodes, CEO of ERS Genomics, said: “We are extremely pleased to be able to provide Otsuka with access to the CRISPR/Cas9 license. We hope this brings significant value to Otsuka as it applies the technology to its internal programs.”
Financial details of the agreement are not disclosed.
Summit Pharmaceuticals International Corporation, a subsidiary of Sumitomo Corporation, serves as the exclusive agent for ERS Genomics in Japan.
ENDS
For high resolution images please contact Zyme Communications
Contacts
Katie Odgaard
Zyme Communications
Tel: +44(0)7787 502 947
Email: katie.odgaard@zymecommunications.com
Record changed: 2022-02-05 |
Advertisement
![Picture [iito] Fighting Customers 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-fighting-customers.jpg)
More documents for ERS Genomics Ltd.
- [1] ERS Genomics Ltd.. (8/17/21). "Press Release: ERS Genomics and Cellular Engineering Technologies Enter CRISPR/Cas9 License Agreement". Dublin & Coralville, IA....
- [2] ERS Genomics Ltd.. (6/1/21). "Press Release: Japanese Patent Office Upholds Key Charpentier/Doudna CRISPR Patent and Allows Third". Dublin....
- [3] ERS Genomics Ltd.. (3/1/21). "Press Release: ERS Genomics Expands Team With Appointment of Jon Kratochvil as VP Business Development". Dublin....
- [4] ERS Genomics Ltd.. (2/16/21). "Press Release: ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement". Dublin & Barcelona....
- [5] ERS Genomics Ltd.. (12/1/20). "Press Release: Vivlion GmbH Signs Worldwide License Agreement With ERS Genomics for CRISPR/Cas9 Patent Portfolio". Dublin & Frankfurt/M.....
- [6] ERS Genomics Ltd.. (10/14/20). "Press Release: ERS Genomics Announces agreement with Fasmac to Commercialize CRISPR/Cas9 Research Reagents in Japan". Dublin & Kanagawa....
- [7] ERS Genomics Ltd.. (9/22/20). "Press Release: ERS Genomics Appoints Michael Arciero as Vice-President of Intellectual Property & Commercial Development". Dublin....
- [8] ERS Genomics Ltd.. (9/14/20). "Press Release: ERS Genomics Provides Comment on US Patent Office Motions Decisions in CRISPR/Cas9 Interference Case". Dublin....
- [9] ERS Genomics Ltd.. (4/2/20). "Press Release: ERS Genomics and Axxam Announce CRISPR/Cas9 License Agreement to Enhance Discovery Services". Dublin & Milan....
- [10] ERS Genomics Ltd.. (2/11/20). "Press Release: ERS Genomics and Aelian Biotechnology Announce CRISPR/Cas9 License Agreement Enabling Aelian’s Unique Screening Platform". Dublin & Vienna....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top